KRAS G12S	Colorectal Cancer	KRAS G12S	Colorectal Cancer	panitumumab Resistant: A1 - Approval panitumumab Resistant : A1	panitumumab Resistant: A1 - Approval panitumumab Resistant : A1
KRAS G12S	Biliary Tract Cancer	KRAS G12S	Biliary Tract Cancer	selumetinib Sensitive: C3 – Early Trials selumetinib Sensitive : C3	selumetinib Sensitive: C3 – Early Trials selumetinib Sensitive : C3
KRAS G12S	Hepatocellular Cancer	KRAS G12S	Hepatocellular Cancer	sorafenib + BAY86-9766 Sensitive: C3 – Early Trials sorafenib + BAY86-9766 Sensitive : C3	sorafenib + BAY86-9766 Sensitive: C3 – Early Trials sorafenib + BAY86-9766 Sensitive : C3
KRAS G12S	Non Small Cell Lung Cancer	KRAS G12S	Non Small Cell Lung Cancer	erlotinib Resistant: C3 – Early Trials erlotinib Resistant : C3	erlotinib Resistant: C3 – Early Trials erlotinib Resistant : C3
KRAS G12S	Non Small Cell Lung Cancer	KRAS G12S	Non Small Cell Lung Cancer	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3
KRAS G12S	Non Small Cell Lung Cancer	KRAS G12S	Non Small Cell Lung Cancer	ASTX029 Sensitive: C4 – Case Studies ASTX029 Sensitive : C4	ASTX029 Sensitive: C4 – Case Studies ASTX029 Sensitive : C4
KRAS G12S	Non Small Cell Lung Cancer	KRAS G12S	Non Small Cell Lung Cancer	JQ-1 Resistant: D – Preclinical JQ-1 Resistant : D	JQ-1 Resistant: D – Preclinical JQ-1 Resistant : D
KRAS G12S	Colorectal Cancer	KRAS G12S	Colorectal Cancer	sunitinib Resistant: D – Preclinical sunitinib Resistant : D	sunitinib Resistant: D – Preclinical sunitinib Resistant : D
KRAS G12S	Lung Adenocarcinoma	KRAS G12S	Lung Adenocarcinoma	trametinib + RAIN-32 Sensitive: D – Preclinical trametinib + RAIN-32 Sensitive : D	trametinib + RAIN-32 Sensitive: D – Preclinical trametinib + RAIN-32 Sensitive : D

KRAS G12S

Associations